ONE STEP AWAY FROM COMMERCIALIZATION
We have refined our technology and our Generation VI Micro-Needle, our final and perfected device, was finalized in 2018. It has passed all testing with 100 per cent reliability. We now must confirm efficacy and safety in order to receive regulatory approvals and be available for potential drug company licences. Our next step is to complete veterinary clinical trials, which shall be conducted in 2022 at the University of Guelph, Ontario.
We are now raising a fourth round of capital to perform human clinical trials and secure licenses with pharmaceutical companies who will then manufacture and sell our device in the human medical market. By investing, you will receive shares and become a co-owner of PKA SoftTouch, and have the potential to profit from the sale of each and every device.
Proof of Concept clinical trials completed & data generated.
PHASE I: Animal Trial
PAHSE II: Human Trial
License with Pharmaceutical Company
Pharmaceutical company receive clinical trial data then fill device with drug they produce.
Needle to market)
Large-scale licensee manufacturers, prefills & sells device.
PKA manufactures & pre-fills device & small-scale licensee sells
Royalties from each sale.
Manufacturing Profit & Royalties from each sale.